Heatwurx (NASDAQ:PCSA) Upgraded to “Sell” at Wall Street Zen

Wall Street Zen upgraded shares of Heatwurx (NASDAQ:PCSA) to a sell rating in a research report sent to investors on Saturday morning.

Several other equities research analysts also recently issued reports on the stock. HC Wainwright lowered their price objective on shares of Heatwurx from $50.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, September 2nd. Zacks Research cut Heatwurx from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 26th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Heatwurx in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Heatwurx presently has a consensus rating of “Hold” and an average target price of $25.00.

Heatwurx Price Performance

NASDAQ PCSA opened at $3.78 on Friday. Heatwurx has a one year low of $2.74 and a one year high of $27.00. The firm has a market cap of $8.58 million, a P/E ratio of -0.11 and a beta of 1.09. The stock’s 50-day moving average is $7.34 and its 200-day moving average is $6.37.

Heatwurx (NASDAQ:PCSA) last posted its earnings results on Thursday, November 6th. The company reported ($1.75) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.00) by $0.25. Equities analysts anticipate that Heatwurx will post -4.05 EPS for the current year.

Heatwurx Company Profile

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.